Table 3.
White blood cell count and inflammatory profiles of the study population at baseline and after six months of add-on PCSK9-i therapy
| FH subjects (n = 56) | FH subjects (n = 56) | ∆ | p Value between the two groups | |
|---|---|---|---|---|
| Baseline | 6-month add-on PCSK9-i | |||
| White blood cell count | ||||
| WBCC, 103/µL | 8.14 ± 1.16 | 7.18 ± 1.26 | − 11.79% | 0.07 |
| NC, 103/µL | 5.21 ± 1.04 | 4.49 ± 0.95 | − 13.82% | < 0.05 |
| LC, 103/µL | 2.14 ± 0.47 | 2.11 ± 0.76 | − 0.01% | 0.67 |
| MC, 103/µL | 0.62 ± 0.17 | 0.55 ± 0.16 | − 11.29% | 0.08 |
| Inflammatory profile | ||||
| hs-CRP, mg/dL | 0.19 (0.08–0.35) | 0.20 (0.09–0.37) | 5.26% | 0.87 |
| NLR | 2.6 ± 0.72 | 2.5 ± 0.7 | − 3.85% | 0.45 |
| MHR | 11.56 ± 4.14 | 10.35 ± 4.16 | − 10.47% | < 0.05 |
Data are presented as mean ± SD, percentages, or median (interquartile range). PCSK9-i = proprotein convertase subtilisin/kexin type 9 inhibitors, FH familial hypercholesterolemia, WBCC white blood cell count, NC neutrophil count, LC lymphocyte count, MC monocyte count, hs-CRP high-sensitivity C-reactive protein, NLR = neutrophil-to-lymphocyte ratio, MHR = monocyte-to-high-density lipoprotein ratio